High Court Refuses To Hear Authorized Generics Suit

Law360, New York (June 25, 2007, 12:00 AM EDT) -- The U.S. Supreme Court on Monday refused to hear the tamoxifen citrate antitrust lawsuit, meaning it will not weigh in on the legal issues surrounding authorized generics.

The move to deny cert was a victory for Barr Pharmaceuticals Inc., which had argued that a patent litigation settlement agreement it reached with AstraZeneca PLC in 1993 did not violate antitrust or consumer protection statutes.

“We have always believed that our patent challenge settlement related to tamoxifen citrate was pro-consumer and pro-competitive, and this has now been definitively...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.